735 related articles for article (PubMed ID: 35305339)
1. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
[TBL] [Abstract][Full Text] [Related]
2. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
Chhatwal JP; Schultz SA; McDade E; Schultz AP; Liu L; Hanseeuw BJ; Joseph-Mathurin N; Feldman R; Fitzpatrick CD; Sparks KP; Levin J; Berman SB; Renton AE; Esposito BT; Fernandez MV; Sung YJ; Lee JH; Klunk WE; Hofmann A; Noble JM; Graff-Radford N; Mori H; Salloway SM; Masters CL; Martins R; Karch CM; Xiong C; Cruchaga C; Perrin RJ; Gordon BA; Benzinger TLS; Fox NC; Schofield PR; Fagan AM; Goate AM; Morris JC; Bateman RJ; Johnson KA; Sperling RA;
Lancet Neurol; 2022 Feb; 21(2):140-152. PubMed ID: 35065037
[TBL] [Abstract][Full Text] [Related]
3. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
[TBL] [Abstract][Full Text] [Related]
4. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
[TBL] [Abstract][Full Text] [Related]
5. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
Cousins O; Schubert JJ; Chandra A; Veronese M; Valkimadi P; Creese B; Khan Z; Arathimos R; Hampshire A; Rosenzweig I; Ballard C; Corbett A; Aasland D; Velayudhan L; O'Neill M; Collier D; Awais R; Sander K; Årstad E; Howes O; Turkheimer F; Hodges A
J Neuroinflammation; 2023 Nov; 20(1):272. PubMed ID: 37990275
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
8. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
[TBL] [Abstract][Full Text] [Related]
9. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.
Sturchio A; Dwivedi AK; Malm T; Wood MJA; Cilia R; Sharma JS; Hill EJ; Schneider LS; Graff-Radford NR; Mori H; Nübling G; El Andaloussi S; Svenningsson P; Ezzat K; Espay AJ;
J Alzheimers Dis; 2022; 90(1):333-348. PubMed ID: 36120786
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
[TBL] [Abstract][Full Text] [Related]
11. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
Gordon BA; Blazey TM; Su Y; Hari-Raj A; Dincer A; Flores S; Christensen J; McDade E; Wang G; Xiong C; Cairns NJ; Hassenstab J; Marcus DS; Fagan AM; Jack CR; Hornbeck RC; Paumier KL; Ances BM; Berman SB; Brickman AM; Cash DM; Chhatwal JP; Correia S; Förster S; Fox NC; Graff-Radford NR; la Fougère C; Levin J; Masters CL; Rossor MN; Salloway S; Saykin AJ; Schofield PR; Thompson PM; Weiner MM; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Lancet Neurol; 2018 Mar; 17(3):241-250. PubMed ID: 29397305
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
13. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
14. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
16. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
17. Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.
Luo J; Agboola F; Grant E; Morris JC; Masters CL; Albert MS; Johnson SC; McDade EM; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Wang G; Li Y; Gordon B; Cruchaga C; Day GS; Levin J; Vöglein J; Ikeuchi T; Suzuki K; Allegri RF; Xiong C;
Brain; 2022 Dec; 145(12):4459-4473. PubMed ID: 35925685
[TBL] [Abstract][Full Text] [Related]
18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
19. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]